FOVEA has built a project portfolio including internal research programs on dry AMD, glaucoma (neuroprotection), retinal dystrophies as well as clinical programs underway for such indications as macular edema, allergic conjunctivitis, or retinitis pigmentosa.
To advance the development and commercialization of its programs, FOVEA is working both independently and through collaborators including industrial partners like Novartis, Genzyme, CombinatoRx, as well as with academic teams, like the Inserm unit U592, the Rothschild Ophthalmological Foundation, or the Johns Hopkins University.
For additional information about FOVEA and its programs, please visit http://www.fovea-pharma.com
About Forbion Capital Partners
Forbion Capital Partners invests in EU and US Life Sciences companies,
developing world-class products and technologies. The Forbion team has
invested in 38 drug development and med tech companies since 2000,
initially as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO
Bank NV. In December of 2006 the group became independent by broadening its
investor base and changing its name to Forbion Capital Partners. In recent
years, the Forbion team has successfully divested from 13 portfolio
companies leaving an active portfolio of 25 companies. Assets under
management currently exceed EUR200 M.
Fovea Pharmaceuticals SA
Chief Financial Officer
Press Contacts :
EuroRSCG C&O Russo Partners, LLC
Marie Carole de Groc Wendy Lau
|SOURCE Fovea Pharmaceuticals SA.|
Copyright©2007 PR Newswire.
All rights reserved